Skip to content

Follow-up of morphologic and functional Lung Damage after severe COVID-19 Pneumonia

Follow-up of morphologic and functional Lung Damage after severe COVID-19 Pneumonia - MR-COVID 19

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00024511
Enrollment
100
Registered
2021-02-23
Start date
2020-05-20
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Residual lung damage after COVID-19 pneumonia

Interventions

Group 1: Patients after hospitalization or complications from severe COVID-19 pneumonia are subject to one to two years of follow-up using morphologic and functional MRI. The standardized MRI protocol

Sponsors

Klinik für Diagnostische und interventionelle RadiologieUniversitätsklinikum Heidelberg
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: a) Patients after severe course of and/or hospitalization for COVID-19 pneumonia b) Patients presenting with lung function impairment developing after COVID-19 pneumonia c) Patients after COVID-19 pneumonia with clinical indications for imaging (typically CT)

Exclusion criteria

Exclusion criteria: a) missing informed consent b) contra-indications for MRI (pacemakers, implants, claustrophobia) c) contra-indications for the contrast material (renal dysfunction, prior adverse reactions) - in these cases the MRI protocol can be limited to the non-ce sequences.

Design outcomes

Primary

MeasureTime frame
To evaluate the quality and prevalence of morphologic and functional lung damage after severe COVID-19 pneumonia over up to two years using lung MRI.

Secondary

MeasureTime frame
1. Establishment of MRI as radiation-free method for the follow-up after severe virus-pneumonia 2. Optimization of the MRI protocol for this purpose 3. Detection of appropriate imaging-based biomarkers (lung perfusion, lesion scores) and combinations with clinical biomarkers 4. To refine the procedures and to gain the necessary experience for the set-up a large multi center-trial, if needed

Countries

Germany

Contacts

Public ContactOyunbileg v. Stackelberg

Klinik für Diagnostische und interventionelle RadiologieUniversitätsklinikum Heidelberg

oyunbileg.stackelberg@med.uni-heidelberg.de062215635847

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026